Global Cell Immunotherapy Platform Market Growth (Status and Outlook) 2026-2032
Description
The global Cell Immunotherapy Platform market size is predicted to grow from US$ 3460 million in 2025 to US$ 10900 million in 2032; it is expected to grow at a CAGR of 18.2% from 2026 to 2032.
The cell immunotherapy platform is a technology platform that uses the patient's own or donor's immune cells, which are cultured, activated, modified or amplified in vitro and then reinfused into the body to treat diseases. The platform activates or enhances the function of the immune system, enabling it to recognize and attack tumor cells, viral infections or other abnormal cells. Common cell immunotherapy methods include CAR-T cell therapy, T cell therapy and dendritic cell vaccines. This platform provides new treatment ideas and means for the treatment of cancer, autoimmune diseases, etc.
United States market for Cell Immunotherapy Platform is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Cell Immunotherapy Platform is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Cell Immunotherapy Platform is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Cell Immunotherapy Platform players cover Kite Pharma, Novartis, Bristol Myers Squibb, Gilead Sciences, Bluebird Bio, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the “Cell Immunotherapy Platform Industry Forecast” looks at past sales and reviews total world Cell Immunotherapy Platform sales in 2025, providing a comprehensive analysis by region and market sector of projected Cell Immunotherapy Platform sales for 2026 through 2032. With Cell Immunotherapy Platform sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cell Immunotherapy Platform industry.
This Insight Report provides a comprehensive analysis of the global Cell Immunotherapy Platform landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Cell Immunotherapy Platform portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cell Immunotherapy Platform market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cell Immunotherapy Platform and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cell Immunotherapy Platform.
This report presents a comprehensive overview, market shares, and growth opportunities of Cell Immunotherapy Platform market by product type, application, key players and key regions and countries.
Segmentation by Type:
Autologous Immune Cell Therapy
Allogeneic Immune Cell Therapy
Segmentation by Application:
Immunotherapy Industry
Biopharmaceutical Industry
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Kite Pharma
Novartis
Bristol Myers Squibb
Gilead Sciences
Bluebird Bio
Celyad Oncology
Autolus Therapeutics
Legend Biotech
Celltrion
Please note: The report will take approximately 2 business days to prepare and deliver.
The cell immunotherapy platform is a technology platform that uses the patient's own or donor's immune cells, which are cultured, activated, modified or amplified in vitro and then reinfused into the body to treat diseases. The platform activates or enhances the function of the immune system, enabling it to recognize and attack tumor cells, viral infections or other abnormal cells. Common cell immunotherapy methods include CAR-T cell therapy, T cell therapy and dendritic cell vaccines. This platform provides new treatment ideas and means for the treatment of cancer, autoimmune diseases, etc.
United States market for Cell Immunotherapy Platform is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Cell Immunotherapy Platform is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Cell Immunotherapy Platform is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Cell Immunotherapy Platform players cover Kite Pharma, Novartis, Bristol Myers Squibb, Gilead Sciences, Bluebird Bio, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the “Cell Immunotherapy Platform Industry Forecast” looks at past sales and reviews total world Cell Immunotherapy Platform sales in 2025, providing a comprehensive analysis by region and market sector of projected Cell Immunotherapy Platform sales for 2026 through 2032. With Cell Immunotherapy Platform sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cell Immunotherapy Platform industry.
This Insight Report provides a comprehensive analysis of the global Cell Immunotherapy Platform landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Cell Immunotherapy Platform portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cell Immunotherapy Platform market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cell Immunotherapy Platform and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cell Immunotherapy Platform.
This report presents a comprehensive overview, market shares, and growth opportunities of Cell Immunotherapy Platform market by product type, application, key players and key regions and countries.
Segmentation by Type:
Autologous Immune Cell Therapy
Allogeneic Immune Cell Therapy
Segmentation by Application:
Immunotherapy Industry
Biopharmaceutical Industry
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Kite Pharma
Novartis
Bristol Myers Squibb
Gilead Sciences
Bluebird Bio
Celyad Oncology
Autolus Therapeutics
Legend Biotech
Celltrion
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
92 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Cell Immunotherapy Platform Market Size by Player
- 4 Cell Immunotherapy Platform by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Cell Immunotherapy Platform Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
